Advanced Medical Optics — Merger or Acquisition (November 2004)
49 slides from Advanced Medical Optics's merger presentation, Nov 10, 2004
Slide 1: Advanced Medical Optics to Acquire VISX
Advanced Medical Optics To Acquire VISX Leadership in Ophthalmic Medical Devices Investor Presentation November 9, 2004 Filed by Advanced Medical Optics, Inc. Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subj
Slide 2: Forward Looking Statements
Forward Looking Statements Our statements in this presentation on slides 4,5,8,9,12,13,15,21,25,27,28,29,30,33,34,36 and 38-46, and elsewhere that refer to AMO’s financial projections or estimated future results, are forward-looking statements that reflect the Company’s current analysis of existing
Slide 3: Transforming AMO for Industry-Leading Performance
TRANSFORMING AMO FOR INDUSTRY-LEADING PERFORMANCE Jim Mazzo AMO President & CEO
Slide 4: AMO Acquires VISX
AMO Acquires VISX Expanded platform for strong, sustainable, profitable growth Creates world’s leading refractive surgical business Establishes $1 billion enterprise with increased earnings power and cash flow potential Provides surgeons and patients a comprehensive portfolio of technologies and bra
Slide 5: Consistent with AMO Plan to Build Shareholder Value
Consistent with AMO Plan to Build Shareholder Value Strengthen leading position in cataract and eye care segments Lead in building global refractive IOL business Ensure technological leadership through continuous innovation Build efficient scalable infrastructure and distribution network Deliver sus
Slide 6: Transform Transcend Transition
Transform Transcend Transition Taking AMO to the Next Level Plan for positioning AMO for industry-leading performance 2002-2003 2004 - 2005 2006+
Slide 7: Transition
Transition Transitioned AMO Following the Spin-Off 2002-2003 Stabilized organization and returned AMO to growth Reprioritized R&D pipeline; launched new products Solidified eye care manufacturing strategy Recapitalized balance sheet
Slide 8: Transition Transform
Transition Transform Reorganized under centralized operating model, improving efficiency and productivity Acquired and largely integrated Pfizer business, solidifying cataract franchise, strengthening refractive offering and enhancing global scale Acquiring VISX, positioning AMO as leader in high-gr
Slide 9: Transcend: Positioning AMO for Industry-Leading Performance
Transcend Transform Transition 2006+ Positioning AMO for Industry-Leading Performance 2002 - 2003 2004 - 2005 Strengthen leadership of three core franchises: cataract, eye care and refractive Continuously innovate to expand portfolio of well-recognized brands Cross-selling synergies from global scal
Slide 10: AMO's Vision Care Life Cycle: At Spin-off
Multifocal IOLs REFRACTIVE CATARACT Microkeratomes Monofocal IOLs EYE CARE Viscoelastics Contact Lens Care Solutions Phaco & Lens Extraction AMO’s Vision Care Life Cycle At Spin-off Improving practitioner productivity and patient outcomes
Slide 11: AMO's Vision Care Life Cycle: Today
Multifocal IOLs Phaco & Lens Extraction GLAUCOMA CATARACT REFRACTIVE Microkeratomes Phakic IOLs Accommodatzing IOLs EYE CARE Viscoelastics Contact Lens Care Solutions Excimer Laser Glaucoma Shunts Monofocal IOLs Vitreo-Retina Contact Lenses AMO’s Vision Care Life Cycle Today Improving practitioner p
Slide 12: AMO and VISX: Compelling Strategic, Technological and Cultural Fit
VISX Brings… Global leader in laser vision correction Ongoing technological innovation Focused, experienced management team Unsurpassed customer support AMO Brings… Global leader Innovator with well-recognized brands Worldwide distribution Experienced management team with record of disciplined execu
Slide 13: Expands Global Size and Scale to Challenge Industry Leaders
2003 Surgical Combined Revenue (1) Of Alcon, B&L and AMO (1) Actual reported sales for refractive and cataract per SEC filings. 2005E Surgical Combined Revenue (2) Of Alcon, B&L and AMO (2) Source: Refractive and cataract estimates from Morgan Stanley and Smith Barney research reports. Pro Forma AMO
Slide 14: Broadens Product Portfolio and Geographic Reach
Broadens Product Portfolio and Geographic Reach Strong global presence, scale and full product breadth Refractive 100% Europe 37% Japan 26% Asia Pacific 9% Americas 28% Eye Care 39% Cataract 59% Refractive 2% (1) LTM period is defined as the last twelve months ended September 24, 2004. Pro Forma for
Slide 15: Global Leadership in Refractive Sector
Global Leadership in Refractive Sector Capitalize on size, brands, global distribution AMO’s global presence provides greater opportunity for laser vision correction expansion in international markets Cross-selling opportunities for lasers, microkeratomes and refractive IOLs Incorporate VISX’s leadi
Slide 16: VISX Overview
VISX OVERVIEW Liz Davila VISX Chairman & CEO
Slide 17: Global Leader in LVC Technology
Global Leader in LVC Technology VISX 29.1% Alcon 12.9% B&L 19.2% Nidek 11% Zeiss 8.2% Schwind 7.7% Wavelight 4.4% Other 7.6% Source: Market Scope , LLC , Laser Installed Base, November 2003
Slide 18: U.S. Procedure Leader
U.S. Procedure Leader 0% 20% 40% 60% 80% 100% Alcon-Summit VISX Nidek LaserSight B & L WaveLight VISX Source: Market Scope , LLC
Slide 19: VISX Model
VISX Model Per Procedure Revenue Drives Highly Profitable Business Model Procedure Gross Profit Margin > 95% 2004 YTD Operating Profit = 38%
Slide 20: VISX Market Leadership
VISX Market Leadership Excellent Clinical Outcomes Exemplary Customer Support Ongoing Technology Leadership
Slide 21: VISX: Ongoing Technology Leadership
VISX: Ongoing Technology Leadership CustomVue Comprehensive measurement and correction Potentially better than contacts or glasses Fourier Wavefront Upgrade Unprecedented resolution for individualized CustomVue treatment Iris Registration First fully automated technology to correct for eye rotation
Slide 22: Powerful Platform for Growth
POWERFUL PLATFORM FOR GROWTH Jim Mazzo AMO President & CEO
Slide 23: Expands Sales Opportunities
27% 10% 12% 12% 6% 17% 16% Expands Sales Opportunities Compete in $3 billion, well-established business with robust growth drivers Surgical Source: Market Scope, November 2003; includes US, Western Europe and Japan only; Eye Care Source: IRI, GFK, AC Nielsen, GERS; includes top 10 geographic regions
Slide 24: Most Complete Line of Innovative Products Among Key Players
Other competitors include LaserSight Technologies, Inc., Carl Zeiss Meditec AG, NIDEK, WaveLight, etc. Viscoelastics Most Complete Line of Innovative Products Among Key Players ___________________________ Key: = Competes = Limited Cataract IOLs Silicone Monofocal Acrylic Monofocal Multifocal Phacoem
Slide 25: Expansive Portfolio of Well Known Brands
CATARACT REFRACTIVE EYE CARE Expansive Portfolio of Well Known Brands Broad brand portfolio supported by innovative technologies
Slide 26: Refractive Opportunities
Pre-Presbyopia Presbyopia Presbyopia/ Cataract High Myopia Low/Moderate Myopia Low/Moderate Hyperopia Moderate/High Hyperopia Laser CK Multifocal Multifocal phakic Accommodating Multifocal Multifocal phakic Accommodating CK/ Monofocal Multifocal phakic Accommodating Monofocal Multifocal phakic Accom
Slide 27: Refractive Opportunity in U.S.
Refractive Opportunity in U.S. Huge unmet need addressable with lasers and refractive IOLs Age Source: Donders’ Table, Clinical Refraction; U.S. Census Bureau 2000 20-29 30-39 40-49 50-59 60-69 70-79 Age in 2004 Age in 2005 Accommodation Eye’s ability to accommodate—change focus from far to near— co
Slide 28: Advantages and Opportunities
Manufacturing Expand capabilities Utilized technical know- how R&D Pool resources, skills Pursue multiple tracks to address refractive conditions Customers More choices for practitioners Broad-based training Access to innovation Distribution Expanded field service Efficient supply chain Leading bran
Slide 29: Creating An Ophthalmic Medical Device Leader
Creating An Ophthalmic Medical Device Leader Highly strategic and consistent with strategy Leading position in major categories Singular focus on medical devices Commitment to innovation Global, well-recognized brands Worldwide distribution network Financial strength to support future growth
Slide 30: Building on Integration Success
BUILDING ON INTEGRATION SUCCESS Randy Meier EVP, Operations & Finance Chief Financial Officer
Slide 31: Path of Progress
2002 2003 2004 Path of Progress Proven focus and execution November 2002: Reprioritized R&D Pipeline June 2003: Recapitalized Balance Sheet November 2003: Purchased Eye Care manufacturing facility in Madrid April 2004: Announced acquisition of Pfizer Surgical Business July 2002: Completed Spin-Off M
Slide 32: Proven Ability to Create Shareholder Value
$0 $1,250 $2,500 June Dec June Dec June Sep $318 $350 $510 $603 $1,305 $1412 $2,509 Pro Forma Market Value Market Value ($ MM) * Based on stock price at end of quarter times pro forma diluted shares outstanding for quarter (as per 10-Q/10-K) Proven Ability to Create Shareholder Value Since Spin-off
Slide 33: Integration Principles and Priorities
Integration Principles and Priorities Extensive due diligence on business and discussion between functional counterparts Emphasis on continuity with the customer and preserving technology leadership Best practices will be taken from both organizations Cross-sell laser, microkeratome and refractive I
Slide 34: Integration Strategy
Integration Strategy Phase I – Pre close Complete detailed integration action plan Complete detailed refractive global marketing strategy Phase 2 – First 30 days post close Combine operations Initiate cost saving initiatives Launch expanded refractive sales and marketing efforts Phase 3 – 30 days+ p
Slide 35: Compelling Financial Rationale
COMPELLING FINANCIAL RATIONALE
Slide 36: AMO/VISX: Ophthalmic Medical Device Leader
AMO/VISX: Ophthalmic Medical Device Leader Platform for Growth, Profitability and Value Creation Comprehensive offering of new technologies Strong competitive position and global presence Focused execution Financial strength to support growth
Slide 37: Transaction Summary
Transaction Summary * Based on the closing price of AMO shares on November 8, 2004 Valuation : $26.52 per VISX share (1) or $1.27 billion Consideration : 87% AMO stock and 13% cash Tax free exchange (1) Exchange Ratio : 0.552 shares of AMO and $3.50 in cash for each VISX share Pro Forma Ownership :
Slide 38: Combined Company Financials
Combined Company Financials Revenue exceeds $1 billion Accelerates sales growth and margin expansion Cash flow in excess of $200 million Generates strong recurring cash flows Diversifies revenue stream Creates third core franchise to balance operating performance Reduces relative exposure to currenc
Slide 39: Contribution Leverages Profitability
82.0% ($835) 58.3% ($71) 61.1% ($128) 64.4% ($153) 78.3% ($525) 18.0% ($184) 41.7% ($51) 38.9% ($82) 35.6% ($85) 21.7% ($145) 0% 20% 40% 60% 80% 100% Net Income EBIT EBITDA Gross Profit Revenue AMO VISX Contribution Leverages Profitability… 2005E Relative Contribution Analysis* * AMO based on 2004 M
Slide 40: Enhanced Financial Profile in 2006
…into Enhanced Financial Profile in 2006 Prior AMO Targets 4-6% 64-65% 17-18% 15-17% Pro Forma Targets 6-8% 66-67% 19-21% 20-22% Gross Margin Operating Margin Earnings Growth Revenue Growth
Slide 41: Strong Cash Flow and Enhanced Balance Sheet
Strong Cash Flow and Enhanced Balance Sheet Revenue mix enhances stability Strong cash flow facilitates rapid deleveraging Track record of debt repayment No incremental capital expenditures required $199 $132 LTM EBITDA (2) $155 $34 Cash 3.0x 4.0x Net Debt/EBITDA 34% 75% Debt/Total Cap $2,206 $762 T
Slide 42: Synergies
Base Business Upside (EBIT: +$5-10 mm) Cost savings from expense management Reorganization yielding productivity benefits Integration of Pfizer acquisition ahead of schedule Cost Savings (EBIT: +$15-20 mm*) $10 mm to be achieved in first 90 days post-closing by reducing administrative costs of the c
Slide 43: Financial Guidance
Financial Guidance Reaffirming 2005 EPS range of $1.65-$1.75* Strength in core business Significant synergies Substantial non-cash charges due to intangibles amortization Accretive in 2006 with synergies Raising growth and margin targets for 2006 Preliminary 2006 EPS guidance of $2.20-$2.30 Cash EPS
Slide 44: Bridge to 2005 Pro Forma and Cash EPS
$1.65 - $1.75 $1.65 - $1.75 $2.05 - $2.15 $1.95 - $2.05 Cash EPS Pro Forma GAAP $1.75 - $1.85 Bridge to 2005 Pro Forma and Cash EPS 5 – 10 (+) AMO Base Business Upside (11) (-) Pfizer Intangibles Amortization (+) Pfizer Intangibles Amortization $118 - $124 (=) AMO Cash Earnings Pre-Transaction (10)
Slide 45: Timeline for Completion
Timeline for Completion November 9: Signing and announcement of Transaction November: Preparation of Joint Proxy Statement File for Antitrust clearance (HSR) December: Mailing of Joint Proxy Statement Shareholder vote Completion of integration planning Jan/Feb 2005: Finalize financing to close trans
Slide 46: Platform for Growth, Profitability and Value Creation
Platform for Growth, Profitability and Value Creation Comprehensive offering of new technologies Clear technology leader committed to continuous innovation Most complete line-up of refractive technologies to offer surgeons Strong competitive position and global presence Solid leading positions in ex
Slide 47: Question & Answer Session
Question & Answer Session
Slide 48: Additional Information
Additional Information AMO and VISX intend to file with the SEC a Registration Statement on Form S-4, which will include a joint proxy statement/prospectus of VISX and AMO and other relevant materials in connection with the proposed transaction. The joint proxy statement/prospectus will be mailed to
Slide 49: Cautionary Statement Regarding Forward-Looking Statements
Cautionary Statement Regarding Forward-Looking Statements Statements contained in this document that refer to AMO's estimated or future results such as statements regarding the timing and certainty of closing the transaction, estimated share ownership percentages, strategic and financial benefits of
Advanced Medical Optics — Merger or Acquisition (November 2004) on 6ix